Nektar Therapeutics

Nektar Therapeutics Reports Operating Results (10-Q)

GuruFocus Updates (Free subscription) | 11/05/2009

By 10qk. Nektar Therapeutics ( NKTR ) filed Quarterly Report for the period ended 2009-09-30. Read more » »

Nektar Therapeutics Reports Third Quarter 2009 Financial Results

PR News Wire (Free subscription) | 11/04/2009

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.

Nektar Therapeutics Reports Third Quarter 2009 Financial Results

Red Orbit (Free subscription) | 11/04/2009

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.

Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets

PR News Wire (Free subscription) | 10/29/2009

SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00...

Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets

Red Orbit (Free subscription) | 10/29/2009

SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets.

Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Platinum-Resistant Ovarian Cancer

Medical News Today (Free subscription) | 10/29/2009

Nektar Therapeutics (Nasdaq: NKTR) announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

• Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer - PR News Wire

Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix

Red Orbit (Free subscription) | 10/11/2009

PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

• Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix - PR News Wire
• Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix - The Earth Times Online Newspaper

AstraZeneca: Nektar Deal to Add Value

SeekingAlpha.com (Free subscription) | 10/05/2009

Zacks.com submits: Recently, AstraZeneca ( AZN ) entered into a licensing deal with Nektar Therapeutics ( NKTR ) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a Phase II trial for the treatment of opioid-induced constipation, the latter, in early stage of development, is intended to treat pain without constipation side effects. Nektar will receive an upfront...

Zacks Bull and Bear of the Day Highlights: Skyworks Solutions, Valero Energy, AstraZeneca, Nektar Therapeutics and Wyeth

Business Wire (Free subscription) | 09/23/2009

CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Skyworks Solutions (SWKS) as the Bull of the Day and Valero Energy (VLO) the Bear of the Day. In addition, Zacks Equity Research provides analysis on AstraZeneca (AZN), Nektar Therapeutics (NKTR) and Wyeth (WYE). Full analysis of all these stocks is available at http://at.zacks.com/?id=2676. Here is a synopsis of all five stocks: Bull of the...

AstraZeneca inks licensing deal with US drug firm

Indian Express (Free subscription) | 09/23/2009

AstraZeneca and US-based Nektar Therapeutics have entered into a worldwide licencing agreement for two drug development programmes, NKTR-118 and NKTR-119.

• AstraZenceca and Nektar sign worldwide agreement for Nektar Drug Development programmes - India Press Release

Nektar on a roll as ovarian cancer drug shows promise

Fiercebiotech (Free subscription) | 09/22/2009

Yesterday shares of Nektar Therapeutics jumped 13 percent on the news that the developer had struck a $1.5 billion licensing deal for two of its development programs with AstraZeneca. This morning its shares rose 11 percent after investigators said a small, early-stage trial of a new ovarian cancer drug produced promising results. Two of the five patients in the trial of NKTR-102 were evaluable for...

Nektar Therapeutics (NKTR) NewsBite - AstraZeneca Deal Lifts NKTR

MarketIntelligenceCenter.com (Free subscription) | 09/21/2009

Nektar Therapeutics (NasdaqNM: NKTR) opened at $9.86. So far today, the stock has hit a low of $9.15 and a high of $9.91. NKTR is now trading at $9.32, up $0.86 (10.17%). Over the last 52 weeks the stock has ranged from a low of $2.45 to a high of $8.61. Shares of NKTR are on the move this morning after the company signed a licensing deal with AstraZeneca (AZN) to develop two of its experimental drug...

Nektar inks potential $1.2 billion deal

bizjournals (Free subscription) | 09/21/2009

Nektar Therapeutics Inc. could win up to $1.2 billion — including a $125 million upfront payment — from AstraZeneca plc in the biggest partnering deal this year for Bay Area biotech companies. (NKTR)

• Nektar inks potential $1.2 billion deal - The San Francisco Business Times

Nektar scores $1.5B development deal with AZ

Fiercebiotech (Free subscription) | 09/21/2009

Nektar Therapeutics will pocket $125 million upfront and up to $1.4 billion in milestones in exchange for licensing two of its therapies for pain and opioid-induced constipation. The pact covers the late-stage constipation drug NKTR-118 alongside the early-stage NKTR-119, which is intended to treat pain without constipation side effects. And San Carlos, CA-based Nektar stands to earn $235 million...

• AstraZeneca on verge of US licensing deal - The Independent

Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119

PR News Wire (Free subscription) | 09/21/2009

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's...